Paper41333210
Assessment of the efficacy of various neoadjuvant anti-HER2 targeted therapies combined with chemotherapy for HER2-positive breast cancer in the real-world setting and development of a predictive model for pathological complete response.
Wang H and 4 others. Front Oncol, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Assessment of the efficacy of various neoadjuvant anti-HER2 targeted therapies combined with chemotherapy for HER2-positive breast cancer in the real-world setting and development of a predictive model for pathological complete response. Papers, record 41333210. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41333210
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Assessment of the efficacy of various neoadjuvant anti-HER2 targeted therapies combined with chemotherapy for HER2-positive breast cancer in the real-world setting and development of a predictive model for pathological complete response.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References55
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39184927 | Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024. | Transl Breast Cancer Res | 2024 | https://conductscience.org/library/papers/39184927 | PubMed |
| 2 | 33446565 | Diffusion-weighted Imaging Allows for Downgrading MR BI-RADS 4 Lesions in Contrast-enhanced MRI of the Breast to Avoid Unnecessary Biopsy. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33446565 | PubMed |
| 3 | 34016991 | HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. | NPJ Breast Cancer | 2021 | https://conductscience.org/library/papers/34016991 | PubMed |
| 4 | 28081544 | Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. | Br J Cancer | 2017 | https://conductscience.org/library/papers/28081544 | PubMed |
| 5 | 38273267 | Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer. | BMC Cancer | 2024 | https://conductscience.org/library/papers/38273267 | PubMed |
| 6 | 36494872 | Evaluation of pretreatment ADC values as predictors of treatment response to neoadjuvant chemotherapy in patients with breast cancer - a multicenter study. | Cancer Imaging | 2022 | https://conductscience.org/library/papers/36494872 | PubMed |
| 7 | 32652460 | Pretreatment apparent diffusion coefficient does not predict therapy response to neoadjuvant chemotherapy in breast cancer. | Breast | 2020 | https://conductscience.org/library/papers/32652460 | PubMed |
| 8 | 24529560 | Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. | Lancet | 2014 | https://conductscience.org/library/papers/24529560 | PubMed |
| 9 | 28938652 | Correlation between apparent diffusion coefficient (ADC) and cellularity is different in several tumors: a meta-analysis. | Oncotarget | 2017 | https://conductscience.org/library/papers/28938652 | PubMed |
| 10 | 31267973 | Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/31267973 | PubMed |
| 11 | 36575513 | Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. | BMC Med | 2022 | https://conductscience.org/library/papers/36575513 | PubMed |
| 12 | 30179110 | Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial. | Radiology | 2018 | https://conductscience.org/library/papers/30179110 | PubMed |
| 13 | 35235873 | Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial. | Eur J Cancer | 2022 | https://conductscience.org/library/papers/35235873 | PubMed |
| 14 | 28115222 | Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. | Eur J Pharm Sci | 2017 | https://conductscience.org/library/papers/28115222 | PubMed |
| 15 | 25580585 | Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy. | J Magn Reson Imaging | 2015 | https://conductscience.org/library/papers/25580585 | PubMed |
| 16 | 32227407 | Role of MRI to Assess Response to Neoadjuvant Therapy for Breast Cancer. | J Magn Reson Imaging | 2020 | https://conductscience.org/library/papers/32227407 | PubMed |
| 17 | 29045232 | Imaging Neoadjuvant Therapy Response in Breast Cancer. | Radiology | 2017 | https://conductscience.org/library/papers/29045232 | PubMed |
| 18 | 31705004 | Diffusion-Weighted Magnetic Resonance Imaging of Patients with Breast Cancer Following Neoadjuvant Chemotherapy Provides Early Prediction of Pathological Response - A Prospective Study. | Sci Rep | 2019 | https://conductscience.org/library/papers/31705004 | PubMed |
| 19 | 38114991 | Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study. | World J Surg Oncol | 2023 | https://conductscience.org/library/papers/38114991 | PubMed |
| 20 | 25891905 | Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer. | Clin Breast Cancer | 2015 | https://conductscience.org/library/papers/25891905 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41333210
GET https://conductscience.org/api/papers/v1/41333210/references?page=2